US 10259826
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
granted A61KA61K31/506A61K31/538
Quick answer
US patent 10259826 (Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds) held by Rigel Pharmaceuticals, Inc. expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/506, A61K31/538, A61K31/541, A61P